Biological mechanisms and clinical implications of endocrine resistance in breast cancer

Clark, 1984, Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer, J Clin Oncol, 2, 1102, 10.1200/JCO.1984.2.10.1102 Wenger, 1993, DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients, Breast Cancer Res Treat, 28, 9, 10.1007/BF00666351 Perou, 2000, Molecular portraits of human breast tumours, Nature, 406, 747, 10.1038/35021093 Sorlie, 2001, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sti U S A, 98, 10869, 10.1073/pnas.191367098 Osborne, 1998, Tamoxifen in the treatment of breast cancer, N Engl J Med, 339, 1609, 10.1056/NEJM199811263392207 Ring, 2004, Mechanisms of tamoxifen resistance, Endocr Relat Cancer, 11, 643, 10.1677/erc.1.00776 Gibson, 2009, Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women, Cochrane Database Syst Rev Sanchez-Munoz, 2009, Optimal adjuvant hormonal therapy in postmenopausal women with hormone-receptor-positive early breast cancer: have we answered the question?, Clin Transl Oncol, 12, 614, 10.1007/s12094-010-0566-9 Brodie, 2011, Adaptive changes result in activation of alternate signaling pathways and acquisition of resistance to aromatase inhibitors, Clin Cancer Res, 17, 42 08, 10.1158/1078-0432.CCR-10-2920 Johnston, 2010, Fulvestrant – a novel endocrine therapy for breast cancer, CurrMed Chem, 17, 902, 10.2174/092986710790820633 Valachis, 2010, Fulvestrant in the treatment of advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials. Crir Rev, Oncol Hematol, 73, 220 Osborne, 2001, Estrogen receptor: current understanding of its activation and modulation, Clin Cancer Res, 7, 4338s Hopp, 2004, Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer, Clin Cancer Res, 10, 7490, 10.1158/1078-0432.CCR-04-1114 McKenna, 1999, Nuclear receptor coregulators: cellular and molecular biology, Endocr Rev, 20, 321 Kushner, 2000, Estrogen receptor pathways to AP-1, J Steroid Biochem Mol Biol, 74, 311, 10.1016/S0960-0760(00)00108-4 Nemere, 2003, Membrane receptors for steroid hormones: signal transduction and physiological significance, J Cell Biochem, 88, 438, 10.1002/jcb.10409 Shi, 2009, Expression of ER-alpha36, a novel variant of estrogen receptor alpha, and resistance to tamoxifen treatment in breast cancer, J Clin Oncol, 27, 3423, 10.1200/JCO.2008.17.2254 Chung, 2002, Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer, IntJ Cancer, 97, 306, 10.1002/ijc.1614 Kahlert, 2000, Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway, J Biol Chem, 275, 18447, 10.1074/jbc.M910345199 Lee, 2002, Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation, Mol Cell Biol, 22, 5835, 10.1128/MCB.22.16.5835-5845.2002 Pontiggia, 2009, Establishment of an in vitro estrogen-dependent mouse mammary tumor model: a new tool to understand estrogen responsiveness and development of tamoxifen resistance in the context of stromal-epithelial interactions, Breast Cancer Res Treat, 116, 247, 10.1007/s10549-008-0113-3 Shou, 2004, Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancerJNarl, Cancer Inst, 96, 926, 10.1093/jnci/djh166 Osborne, 1995, Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer, J Natl Cancer Inst, 87, 746, 10.1093/jnci/87.10.746 Lake, 2002, Aromatase inhibitors in breast cancer: an update, Cancer Control, 9, 490, 10.1177/107327480200900606 Goel, 2009, LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women, Cochrane Database Syst Rev Gnant, 2009, Endocrine therapy plus zoledronic acid in premenopausal breast cancer, N EnglJ Med, 360, 679, 10.1056/NEJMoa0806285 Herynk, 2004, Estrogen receptor mutations in human disease, Endocr Rev, 25, 869, 10.1210/er.2003-0010 Iwase, 1995, Loss of heterozygosity of the oestrogen receptor gene in breast cancer, Br J Cancer, 71, 448, 10.1038/bjc.1995.91 Adams, 2007, The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines, Mol Endocrinol, 21, 1132, 10.1210/me.2007-0022 Gururaj, 2006, Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations, Clin Cancer Res, 12, 1001s, 10.1158/1078-0432.CCR-05-2110 Lavinsky, 1998, Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes, Proc Natl Acad SciUSA, 95, 2920, 10.1073/pnas.95.6.2920 Osborne, 2003, Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. JNar/, Cancer Inst, 95, 353, 10.1093/jnci/95.5.353 Schiff, 2000, Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo, J Natl Cancer Inst, 92, 1926, 10.1093/jnci/92.23.1926 Zhou, 2007, Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer, BMC Cancer, 7, 59, 10.1186/1471-2407-7-59 Massarweh, 2008, Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function, Cancer Res, 68, 826, 10.1158/0008-5472.CAN-07-2707 Lupien, 2010, Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance, Genes Dev, 24, 2219, 10.1101/gad.1944810 Arpino, 2004, HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study, Clin Cancer Res, 10, 5670, 10.1158/1078-0432.CCR-04-0110 De Laurentiis, 2005, A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer, Clin Cancer Res, 11, 4741, 10.1158/1078-0432.CCR-04-2569 Konecny, 2003, Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer, J Natl Cancer Inst, 95, 142, 10.1093/jnci/95.2.142 Miller, 2009, Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer, Cancer Res, 69, 4192, 10.1158/0008-5472.CAN-09-0042 Cui, 2003, Mol Endocrinol, 17, 575, 10.1210/me.2002-0318 Creighton, 2010, Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer, Breast Cancer Res, 12, R40, 10.1186/bcr2594 deGraffenried, 2004, Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity, Clin Cancer Res, 10, 8059, 10.1158/1078-0432.CCR-04-0035 DeGraffenried, 2003, Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high Akt activity, Ann Oncol, 14, 1051, 10.1093/annonc/mdg291 Campbell, 2001, Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J, Biol Chem, 276, 9817, 10.1074/jbc.M010840200 Bunone, 1996, Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation, EMBOJ, 15, 2174, 10.1002/j.1460-2075.1996.tb00571.x Kato, 1995, Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase, Science, 270, 1491, 10.1126/science.270.5241.1491 Gutierrez, 2005, Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase, J Clin Oncol, 23, 2469, 10.1200/JCO.2005.01.172 Butt, 2005, Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin Dl and cyclin E, Endocr Relat Cancer, 12, S47, 10.1677/erc.1.00993 Chu, 2008, The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy, Nat Rev Cancer, 8, 253, 10.1038/nrc2347 Perez-Tenorio, 2006, Cytoplasmic p21WAFl/CIPl correlates with Akt activation and poor response to tamoxifen in breast cancer, IntJ Oncol, 28, 1031 Kumar, 1996, Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells, Clin Cancer Res, 2, 1215 Encarnacion, 1993, Measurement of steroid hormone receptors in breast cancer patients on tamoxifen, Breast Cancer Res Treat, 26, 237, 10.1007/BF00665801 Lopez-Tarruella, 2007, The dynamics of estrogen receptor status in breast cancer: re-shaping the paradigm, Clin Cancer Res, 13, 6921, 10.1158/1078-0432.CCR-07-1399 Bayliss, 2007, Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response, Clin Cancer Res, 13, 7029, 10.1158/1078-0432.CCR-07-0587 Carroll, 2006, Genome-wide analysis of estrogen receptor binding sites, Nat Genet, 38, 1289, 10.1038/ng1901 Arpino, 2008, Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance, Endocr Rev, 29, 217, 10.1210/er.2006-0045 Musgrove, 2009, Biological determinants of endocrine resistance in breast cancer, Nat Rev Cancer, 9, 631, 10.1038/nrc2713 Tovey, 2005, Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer?, Clin Cancer Res, 11, 4835, 10.1158/1078-0432.CCR-05-0196 Ellis, 2001, Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial J, Clin Oncol, 19, 3808, 10.1200/JCO.2001.19.18.3808 Smith, 2005, Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial, J Clin Oncol, 23, 5108, 10.1200/JCO.2005.04.005 Ellis, 2006, Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole, J Clin Oncol, 24, 3019, 10.1200/JCO.2005.04.3034 Dowsett, 2008, Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial, J Clin Oncol, 26, 1059, 10.1200/JCO.2007.12.9437 Viale, 2011, Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial, Ann Oncol, 10.1093/annonc/mdq738 Bartlett, 2011, Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial, J Clin Oncol, 29, 1531, 10.1200/JCO.2010.30.3677 Howell, 1995, Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer, Lancet, 345, 29, 10.1016/S0140-6736(95)91156-1 Robertson, 2010, Activity of fulvestrant in HER2-overexpressing advanced breast cancer, Ann Oncol, 21, 1246, 10.1093/annonc/mdp447 Kaufman, 2009, Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study, J Clin Oncol, 27, 5529, 10.1200/JCO.2008.20.6847 Marcom, 2007, The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers, Breast Cancer Res Treat, 102, 43, 10.1007/s10549-006-9307-8 Johnston, 2009, Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer, J Clin Oncol, 27, 5538, 10.1200/JCO.2009.23.3734 Osborne, 2011, Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study, Clin Cancer Res, 17, 1147, 10.1158/1078-0432.CCR-10-1869 Cristofanilli, 2010, Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer, Clin Cancer Res, 16, 1904, 10.1158/1078-0432.CCR-09-2282 Dalenc, 2010, Tipifarnib plus tamoxifen in tamoxifen-resistant metastatic breast cancer: a negative phase II and screening of potential therapeutic markers by proteomic analysis, Clin Cancer Res, 16, 1264, 10.1158/1078-0432.CCR-09-1192 Johnston, 2008, A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy, Breast Cancer Res Treat, 110, 327, 10.1007/s10549-007-9726-1 Carpenter, 2005, Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. ASCO Annual Meeting Proceedings, J Clin Oncol, 23 Bachelot T, Bourgier C, Cropet C, Guastalla J-P, Ferrero J-M, Leger-Falandry C, et al. TAMRAD: a GINECO randomized phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (Al). Proceedings 2010 San Antonio Breast Cancer Symposium 2010: Abstract Sl-6. Chow, 2006, Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer, Breast Cancer Res Treat, 97 Smith, 2007, A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J din, Oncol, 25, 3816 Polychronis, 2005, Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial, Lancet Oncol, 6, 383, 10.1016/S1470-2045(05)70176-5 Baselga, 2009, Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer, Clin Oncol, 27, 2630, 10.1200/JCO.2008.18.8391